Cite
HARVARD Citation
Shoji, T. et al. (2022). Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023. Cancer science. 113 (1), pp. 240-250. [Online].